Blog
RSS FeedPosted by Michael Wonder on 09 Mar 2020
Regulating medicines in a globalised world with increased recognition and reliance among regulators
5 March 2020 - Research and development of pharmaceuticals are now complex global endeavours, with drug companies operating worldwide using global ...
Posted by Michael Wonder on 31 Aug 2018
Crossing the global health care quality chasm: a key component of universal health coverage
31 August 2018 - Despite years of investment and research, the quality of health care in every country is much ...
Posted by Michael Wonder on 05 Aug 2015
PTAC recommended the listing of Perjeta (pertuzumab) for patients with metastatic breast cancer
At its meeting on 13-14 February 2014, the Committee reviewed an application from Roche for the funding of pertuzumab (Perjeta) ...
Posted by Michael Wonder on 05 Aug 2015
NICE issues final draft guidance recommending enzalutamide for prostate cancer
People with hormone-relapsed prostate cancer that has spread to other parts of the body and have been treated with the ...
Posted by Michael Wonder on 05 Aug 2015
Clovis Oncology receives breakthrough therapy designation for CO-1686 for the second-line treatment of EGFR mutant non small-cell lung cancer in patients with the T790M mutation
Clovis Oncology announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the Company’s investigational agent CO-1686 ...